3/25/2015 JuvenileIdiopathicArthritisUveitis
http://emedicine.medscape.com/article/1209891overview 1/5
JuvenileIdiopathicArthritisUveitisAuthor:ManoletteRRoque,MD,MBAChiefEditor:HamptonRoySr,MDmore...
Updated:Jun19,2012
Background
Approximately6%ofallcasesofuveitisariseinchildren.[1]Themostfrequentcauseofchronicintraocularinflammationamongchildrenisjuvenileidiopathicarthritis(JIA)associateduveitis.[2]Aunifyingclassification,juvenileidiopathicarthritis(JIA),encompassingjuvenilechronicarthritisandjuvenilerheumatoidarthritis(JRA),hasbeendevelopedbyconsensus.
Acuteanterioruveitiswithhypopyoninachild.CourtesyofManoletteRoque,MD,OphthalmicConsultantsPhilippinesCo,EYEREPUBLICOphthalmologyClinic.
Chroniciridocyclitisoccursin1020%ofallpatientswithJIA.[3,4,5,6]ChronicuveitischaracteristicallyisasymptomaticinchildrenwithJIA,leadingtoinsidiousbutprogressivemorbidityandpossibleblindness.Theinvolvedeyesoftenarewhiteandquietappearing,yet3040%ofpatientswithJIAassociateduveitisexperienceseverelossofvisionasaconsequenceoftheircondition.
JIA,asdefinedbytheAmericanRheumatismAssociation(ARA),isthepresenceofarthritis(chronic,seronegative,andperipheral)beforeage16years,ofatleast3monthsduration,whenothercauseshavebeenexcluded.Itisclassifiedby1of3typesofonset.[7]
Oligoarticular(pauciarticular)onsetJIA(4060%)iscommoningirls(5:1).Peakageofonsetisatage2years.Fourorfewerjointsareinvolvedduringthefirst6monthsofthedisease(oftenasymmetric).Oligoarticularonsetcommonlyinvolvesthekneesand,lessfrequently,theanklesandwrists.Thearthritismaybeevanescent,rarelydestructive,andradiologicallyinsignificant.Approximately75%ofthesepatientstestpositiveforantinuclearantibody(ANA).Thismodeofonsetrarelyisassociatedwithsystemicsigns.Ahighriskforuveitisexists.[8]
PolyarticularonsetJIA(2040%)iscommoningirls(3:1).Peakageofonsetisatage3years.Itinvolves5ormorejointsduringthefirst6monthsofthedisease.PolyarticularonsetJIAcommonlyinvolvesthesmalljointsofthehandand,lessfrequently,thelargerjointsoftheknee,ankle,orwrist.Asymmetricarthritismaybeacuteorchronicandmaybedestructivein15%ofpatients.ImmunoglobulinM(IgM)rheumatoidfactor(RF)ispresentin10%ofchildrenwiththisJIAsubgroup.Itisassociatedwithsubcutaneousnodules,erosions,andapoorprognosis.Approximately40%ofthesepatientstestpositiveforANA.Systemicsymptoms,includinganorexia,anemia,andgrowthretardation,aremoderate.Anintermediateriskforuveitisexists.
SystemiconsetJIA(1020%)isequalfrequencyinboysandgirlsandcanappearatanyage.Symmetricpolyarthritisispresentandmaybedestructivein25%ofpatients.Hands,wrists,feet,ankles,elbows,knees,hips,shoulders,cervicalspine,andjawmaybeinvolved.ANAispositiveinonly10%ofthepatients.Systemiconsetisassociatedwithfever(highineveningandnormalinmorning),macularrash,leukocytosis,lymphadenopathy,andhepatomegaly.Pericarditis,pleuritis,splenomegaly,andabdominalpainlesscommonlyareobserved.Alowriskforuveitisexists.
Pathophysiology
ThecauseofuveitisandarthritisinJIAremainsunknown.[9]Akintomanyotherautoimmunediseases,thetargetantigenisunidentified.Immunereactionstoocularantigens(Santigenoririsantigen)havebeenstudiedhowever,theiractualrole(activeorpassive)isunknown.Thecourseofthediseasemaybeshortandlimitedorprogressiveandsevere.
Epidemiology
Frequency
UnitedStates
JIAhasanestimatedprevalenceofabout113casesper100,000children.ItisestimatedthatJIAafflicts60,00070,000children,butonlyaminoritydevelopeyedisease.IncidenceofeyediseaseintheJIApopulationisuncertain,butitisbelievedtobearound10%.[7]
Mortality/Morbidity
MorbidityinJIAassociateduveitismayresulteitherfromlackoftreatmentorfromoverzealoustreatment.Mortalitymayresultfromthelatter.
3/25/2015 JuvenileIdiopathicArthritisUveitis
http://emedicine.medscape.com/article/1209891overview 2/5
Race
Noknownracialpredilectionexists.
Sex
Astrongpredilectionexistsforgirls.Thegirltoboyratiois4:1.
Age
JIAisachildhooddisease.
Bydefinition,JIAoccursinchildrenyoungerthanage16years.Inviewofthefactthattheoculardiseasecanfollowthesystemicdiseasebynumerousyears,alotofpatientsarewellbeyondtheirteenswhentheyareexaminedandtreatedforuveitis.[10]
ContributorInformationandDisclosuresAuthorManoletteRRoque,MD,MBAGeneralManager,FullPartner,OphthalmicConsultantsPhilippinesCo.PresidentandCEO,ChiefRefractiveSurgeon,EYEREPUBLICOphthalmologyClinicSectionChief,OcularImmunologyandUveitis,DepartmentofOphthalmology,AsianHospitalandMedicalCenterSectionChief,OcularImmunologyandUveitis,InternationalEyeInstitute,StLuke'sMedicalCenterGlobalCitySeniorEyeSurgeon,TheLASIKSurgeryClinicDirector,AMCEyeCenter,AlabangMedicalCenterPresident,PhilippineOcularInflammationSociety
ManoletteRRoque,MD,MBAisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmicExecutives,AmericanAcademyofOphthalmology,AmericanSocietyofCataractandRefractiveSurgery,AmericanSocietyofOphthalmicAdministrators,AmericanUveitisSociety,InternationalOcularInflammationSociety,PhilippineMedicalAssociation,PhilippineOcularInflammationSociety,andPhilippineSocietyofCataractandRefractiveSurgery
Disclosure:Nothingtodisclose.
Coauthor(s)BarbaraLRoque,MDFullPartner,OphthalmicConsultantsPhilippinesCoServiceChief,PediatricOphthalmologyandStrabismus,DepartmentofOphthalmology,AsianHospitalandMedicalCenterActiveStaff,InternationalEyeInstitute,StLuke'sMedicalCenterGlobalCityVisitingOphthalmologist,AMCEyeCenter,AlabangMedicalCenter
BarbaraLRoque,MDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanAssociationforPediatricOphthalmologyandStrabismus,AmericanSocietyofCataractandRefractiveSurgery,PhilippineAcademyofOphthalmology,PhilippineSocietyofCataractandRefractiveSurgery,andPhilippineSocietyofPediatricOphthalmolo
Disclosure:Nothingtodisclose.
ElisabettaMiserocchi,MDFellowinImmunologyandUveitisService,DepartmentofOphthalmology,HarvardMedicalSchool
Disclosure:Nothingtodisclose.
CStephenFoster,MD,FACS,FACR,FAAOClinicalProfessorofOphthalmology,HarvardMedicalSchoolConsultingStaff,DepartmentofOphthalmology,MassachusettsEyeandEarInfirmaryFounderandPresident,OcularImmunologyandUveitisFoundation,MassachusettsEyeResearchandSurgeryInstitution
CStephenFoster,MD,FACS,FACR,FAAOisamemberofthefollowingmedicalsocieties:AlphaOmegaAlpha,AmericanAcademyofOphthalmology,AmericanAssociationofImmunologists,AmericanCollegeofRheumatology,AmericanCollegeofSurgeons,AmericanFederationforClinicalResearch,AmericanMedicalAssociation,AmericanSocietyforMicrobiology,AmericanUveitisSociety,AssociationforResearchinVisionandOphthalmology,MassachusettsMedicalSociety,RoyalSocietyofMedicine,andSigmaXi
Disclosure:Nothingtodisclose.
SpecialtyEditorBoardAndrewADahl,MDDirectorofOphthalmologyTeaching,MidHudsonFamilyPracticeInstitute,TheInstituteforFamilyHealthAssistantProfessorofSurgery(Ophthalmology),NewYorkCollegeofMedicine
AndrewADahl,MDisamemberofthefollowingmedicalsocieties:AlphaOmegaAlpha,AmericanAcademyofOphthalmology,AmericanCollegeofSurgeons,AmericanMedicalAssociation,AmericanSocietyofCataractandRefractiveSurgery,andWildernessMedicalSociety
Disclosure:Nothingtodisclose.
SimonKLaw,MD,PharmDClinicalProfessorofHealthSciences,DepartmentofOphthalmology,JulesSteinEyeInstitute,UniversityofCalifornia,LosAngeles,DavidGeffenSchoolofMedicine
SimonKLaw,MD,PharmDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanGlaucomaSociety,andAssociationforResearchinVisionandOphthalmology
Disclosure:Nothingtodisclose.
RChristopherWalton,MDProfessor,DirectorofUveitisandOcularInflammatoryDiseaseService,DepartmentofOphthalmology,UniversityofTennesseeCollegeofMedicine
RChristopherWalton,MDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanCollegeofHealthcareExecutives,AmericanUveitisSociety,AssociationforResearch
3/25/2015 JuvenileIdiopathicArthritisUveitis
http://emedicine.medscape.com/article/1209891overview 3/5
inVisionandOphthalmology,andRetinaSociety
Disclosure:Nothingtodisclose.
LanceLBrown,OD,MDOphthalmologist,AffiliatedWithFreemanHospitalandStJohn'sHospital,RegionalEyeCenter,Joplin,Missouri
Disclosure:Nothingtodisclose.
ChiefEditorHamptonRoySr,MDAssociateClinicalProfessor,DepartmentofOphthalmology,UniversityofArkansasforMedicalSciences
HamptonRoySr,MDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanCollegeofSurgeons,andPanAmericanAssociationofOphthalmology
Disclosure:Nothingtodisclose.
AdditionalContributorsTheauthorsandeditorsofMedscapeReferencegratefullyacknowledgetheassistanceofRyanIHuffman,MD,withtheliteraturereviewandreferencingforthisarticle.
References
1. NguyenQD,FosterCS.Savingthevisionofchildrenwithjuvenilerheumatoidarthritisassociateduveitis.JAMA.Oct71998280(13):11334.[Medline].
2. PivnsaloHietanenT,TuominenJ,SaariKM.Uveitisinchildren:populationbasedstudyinFinland.ActaOphthalmolScand.Feb200078(1):848.[Medline].
3. BooneMI,MooreTL,CruzOA.Screeningforuveitisinjuvenilerheumatoidarthritis.JPediatrOphthalmolStrabismus.JanFeb199835(1):413.[Medline].
4. KotaniemiK,KaipiainenSeppanenO,SavolainenA,etal.Apopulationbasedstudyonuveitisinjuvenilerheumatoidarthritis.ClinExpRheumatol.JanFeb199917(1):11922.[Medline].
5. MallesonP.Prevalenceandoutcomeofuveitisinaregionalcohortofpatientswithjuvenilerheumatoidarthritis.JRheumatol.Jun199825(6):1242.[Medline].
6. KesenMR,SetlurV,GoldsteinDA.Juvenileidiopathicarthritisrelateduveitis.IntOphthalmolClin.Summer200848(3):2138.[Medline].
7. WrightT,CronRQ.PediatricrheumatologyfortheadultrheumatologistII:uveitisinjuvenileidiopathicarthritis.JClinRheumatol.Aug200713(4):20510.[Medline].
8. KanskiJJ.Anterioruveitisinjuvenilerheumatoidarthritis.ArchOphthalmol.Oct197795(10):17947.[Medline].
9. GallagherKT,BernsteinB.Juvenilerheumatoidarthritis.CurrOpinRheumatol.Sep199911(5):3726.[Medline].
10. KotaniemiK.Lateonsetuveitisinjuveniletypechronicpolyarthritiscontrolledwithprednisolone,cyclosporinAandmethotrexate.ClinExpRheumatol.JulAug199816(4):46971.[Medline].
11. DonnRP,FarhanAJ,BarrettJH,etal.Absenceofassociationbetweeninterleukin1alphaandoligoarticularjuvenilechronicarthritisinUKpatients.Rheumatology(Oxford).Feb199938(2):1715.[Medline].
12. ReiningaJK,LosLI,WulffraatNM,etal.Theevaluationofuveitisinjuvenileidiopathicarthritis(JIA)patients:arecurrentophthalmologicscreeningguidelinesadequate?.ClinExpRheumatol.MarApr200826(2):36772.[Medline].
13. YenJH,TsaiWC,TsaiJJ,etal.HLADMAandHLADMBgenotypinginpatientswithrheumaticdiseases.KaohsiungJMedSci.May199915(5):2637.[Medline].
14. CassidyJT.Medicalmanagementofchildrenwithjuvenilerheumatoidarthritis.Drugs.Nov199958(5):83150.[Medline].
15. CeislerEJ,FosterCS.Juvenilerheumatoidarthritisanduveitis:minimizingtheblindingcomplications.IntOphthalmolClin.Winter199636(1):91107.[Medline].
16. HemadyRK,BaerJC,FosterCS.Immunosuppressivedrugsinthemanagementofprogressive,corticosteroidresistantuveitisassociatedwithjuvenilerheumatoidarthritis.IntOphthalmolClin.Winter199232(1):24152.[Medline].
17. YuEN,MeniconiME,TufailF,etal.Outcomesoftreatmentwithimmunomodulatorytherapyinpatientswithcorticosteroidresistantjuvenileidiopathicarthritisassociatedchroniciridocyclitis.OculImmunolInflamm.SepOct200513(5):35360.[Medline].
18. KilmartinDJ,ForresterJV,DickAD.CyclosporinAtherapyinrefractorynoninfectiouschildhooduveitis.BrJOphthalmol.Jul199882(7):73742.[Medline].
19. OkadaAA.Immunomodulatorytherapyforocularinflammatorydisease:abasicmanualandreviewoftheliterature.OculImmunolInflamm.SepOct200513(5):33551.[Medline].
20. ShettyAK,ZganjarBE,EllisGSJr,etal.Lowdosemethotrexateinthetreatmentofseverejuvenilerheumatoidarthritisandsarcoidiritis.JPediatrOphthalmolStrabismus.MayJun199936(3):1258.[Medline].
21. SingerNG,McCuneWJ.Updateonimmunosuppressivetherapy.CurrOpinRheumatol.May
3/25/2015 JuvenileIdiopathicArthritisUveitis
http://emedicine.medscape.com/article/1209891overview 4/5
199810(3):16973.[Medline].
22. WeissAH,WallaceCA,SherryDD.Methotrexateforresistantchronicuveitisinchildrenwithjuvenilerheumatoidarthritis.JPediatr.Aug1998133(2):2668.[Medline].
23. ImrieFR,DickAD.Biologicsinthetreatmentofuveitis.CurrOpinOphthalmol.Nov200718(6):4816.[Medline].
24. TynjalaP,KotaniemiK,LindahlP,etal.Adalimumabinjuvenileidiopathicarthritisassociatedchronicanterioruveitis.Rheumatology(Oxford).Mar200847(3):33944.[Medline].
25. HeiligenhausA,MingelsA,HeinzC,etal.Methotrexateforuveitisassociatedwithjuvenileidiopathicarthritis:valueandrequirementforadditionalantiinflammatorymedication.EurJOphthalmol.SepOct200717(5):7438.[Medline].
26. IlowiteNT.Updateonbiologicsinjuvenileidiopathicarthritis.CurrOpinRheumatol.Sep200820(5):6138.[Medline].
27. BenEzraD,CohenE.Cataractsurgeryinchildrenwithchronicuveitis.Ophthalmology.Jul2000107(7):125560.[Medline].
28. HollandGN.Intraocularlensimplantationinpatientswithjuvenilerheumatoidarthritisassociateduveitis:anunresolvedmanagementissue.AmJOphthalmol.Aug1996122(2):2557.[Medline].
29. AcevedoS,QuinonesK,RaoV,etal.Cataractsurgeryinchildrenwithjuvenileidiopathicarthritisassociateduveitis.IntOphthalmolClin.Spring200848(2):17.[Medline].
30. SijssensKM,LosLI,RothovaA,SchellekensPA,vandeDoesP,StilmaJS.Longtermocularcomplicationsinaphakicversuspseudophakiceyesofchildrenwithjuvenileidiopathicarthritisassociateduveitis.BrJOphthalmol.Sep201094(9):11459.[Medline].
31. DanaMR,MerayoLlovesJ,SchaumbergDA,etal.Visualoutcomesprognosticatorsinjuvenilerheumatoidarthritisassociateduveitis.Ophthalmology.Feb1997104(2):23644.[Medline].
32. FoxGM,FlynnHWJr,DavisJL,etal.Causesofreducedvisualacuityonlongtermfollowupaftercataractextractioninpatientswithuveitisandjuvenilerheumatoidarthritis.AmJOphthalmol.Dec151992114(6):70814.[Medline].
33. OzdalPC,ViannaRN,DeschnesJ.Visualoutcomeofjuvenilerheumatoidarthritisassociateduveitisinadults.OculImmunolInflamm.Feb200513(1):338.[Medline].
34. GrayT,KanskiJ,LightmanS.Steroidresponsivediscneovascularisationinuveitisassociatedwithjuvenilechronicarthritis.BrJOphthalmol.Mar199882(3):3278.[Medline].
35. DucosdeLahitteG,TerradaC,TranTH,etal.Maculopathyinuveitisofjuvenileidiopathicarthritis:anopticalcoherencetomographystudy.BrJOphthalmol.Jan200892(1):649.[Medline].
36. WolfMD,LichterPR,RagsdaleCG.Prognosticfactorsintheuveitisofjuvenilerheumatoidarthritis.Ophthalmology.Oct198794(10):12428.[Medline].
37. AggarwalA,MisraRN.JuvenilerheumatoidarthritisinIndiararityofantinuclearantibodyanduveitis.IndianJPediatr.MayJun199663(3):3014.[Medline].
38. AkinciA,CakarN,UncuN,etal.Keratoconjunctivitissiccainjuvenilerheumatoidarthritis.Cornea.Sep200726(8):9414.[Medline].
39. AnesiSD,FosterCS.Theimportanceofrecognizingjuvenileidiopathicarthritisassociateduveitisandpreventingblindnessfromit.ArthritisCareRes(Hoboken).Jan92012[Medline].
40. AngelesHanS,YehS.Preventionandmanagementofcataractsinchildrenwithjuvenileidiopathicarthritisassociateduveitis.CurrRheumatolRep.Apr201214(2):1429.[Medline].
41. AngelesHanST,GriffinKW,HarrisonMJ,LehmanTJ,LeongT,RobbRR,etal.Developmentofavisionrelatedqualityoflifeinstrumentforchildrenages818yearsforuseinjuvenileidiopathicarthritisassociateduveitis.ArthritisCareRes(Hoboken).Sep201163(9):125461.[Medline].[FullText].
42. BaldassanoVFJr.Ocularmanifestationsofrheumaticdiseases.CurrOpinOphthalmol.Dec19989(6):858.[Medline].
43. DollfusH.Eyeinvolvementinchildren'srheumaticdiseases.BaillieresClinRheumatol.May199812(2):30928.[Medline].
44. GrajewskiRS,ZurekImhoffB,RoeselM,HeinzC,HeiligenhausA.FavourableoutcomeaftercataractsurgerywithIOLimplantationinuveitisassociatedwithjuvenileidiopathicarthritis.ActaOphthalmol.Feb112011[Medline].
45. HeiligenhausA,FoeldvariI,EdelstenC,SmithJR,SaurenmannRK,BodaghiB,etal.Proposedoutcomemeasuresforprospectiveclinicaltrialsinjuvenileidiopathicarthritisassociateduveitis:Aconsensuseffortfromthemultinationalinterdisciplinaryworkinggroupforuveitisinchildhood(MIWGUC).ArthritisCareRes(Hoboken).Mar212012[Medline].
46. HeiligenhausA,MichelsH,SchumacherC,KoppI,NeudorfU,NiehuesT,etal.Evidencebased,interdisciplinaryguidelinesforantiinflammatorytreatmentofuveitisassociatedwithjuvenileidiopathicarthritis.RheumatolInt.Nov152011[Medline].
47. HeiligenhausA,MiserocchiE,HeinzC,GerloniV,KotaniemiK.TreatmentofsevereuveitisassociatedwithjuvenileidiopathicarthritiswithantiCD20monoclonalantibody(rituximab).Rheumatology(Oxford).Aug201150(8):13904.[Medline].
48. HeinzC,SchumacherC,RoeselM,HeiligenhausA.Elevatedintraocularpressureinuveitisassociatedwithjuvenileidiopathicarthritisassociateduveitis,oftendetectedafterachievinginactivity.BrJ
3/25/2015 JuvenileIdiopathicArthritisUveitis
http://emedicine.medscape.com/article/1209891overview 5/5
MedscapeReference2011WebMD,LLC
Ophthalmol.Jan201296(1):1401.[Medline].
49. HoeveM,KalininaAyusoV,SchalijDelfosNE,LosLI,RothovaA,deBoerJH.Theclinicalcourseofjuvenileidiopathicarthritisassociateduveitisinchildhoodandpuberty.BrJOphthalmol.Mar72012[Medline].
50. KalininaAyusoV,vandeWinkelEL,RothovaA,deBoerJH.Relapserateofuveitispostmethotrexatetreatmentinjuvenileidiopathicarthritis.AmJOphthalmol.Feb2011151(2):21722.[Medline].
51. KenawyN,ClearyG,MewarD,BeareN,ChandnaA,PearceI.Abatacept:apotentialtherapyinrefractorycasesofjuvenileidiopathicarthritisassociateduveitis.GraefesArchClinExpOphthalmol.Feb2011249(2):297300.[Medline].
52. KotaniemiK,SilH,KautiainenH.Longtermefficacyofadalimumabinthetreatmentofuveitisassociatedwithjuvenileidiopathicarthritis.ClinOphthalmol.20115:14259.[Medline].[FullText].
53. QianY,AcharyaNR.Juvenileidiopathicarthritisassociateduveitis.CurrOpinOphthalmol.Nov201021(6):46872.[Medline].[FullText].
54. RabinovichCE.Treatmentofjuvenileidiopathicarthritisassociateduveitis:challengesandupdate.CurrOpinRheumatol.Sep201123(5):4326.[Medline].
55. SinghS,SalariaM,KumarL,etal.ClinicoimmunologicalprofileofjuvenilerheumatoidarthritisatChandigarh.IndianPediatr.May199936(5):44954.[Medline].
56. TappeinerC,HeinzC,RoeselM,HeiligenhausA.Elevatedlaserflarevaluescorrelatewithcomplicatedcourseofanterioruveitisinpatientswithjuvenileidiopathicarthritis.ActaOphthalmol.Sep201189(6):e5217.[Medline].